Solasia Pharma KK (JP:4597) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Solasia Pharma K.K. has revised its earnings forecast for 2024, anticipating a significant decrease in revenue due to sluggish product shipments and delays in out-licensing DARVIAS® in China. The company now expects an operating loss of 1,150 million yen, driven by reduced revenue expectations and lower R&D and SG&A expenses. Solasia remains focused on finalizing licensing agreements for DARVIAS® in China and other regions as a priority.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.